Home > Boards > US Listed > Biotechs > Halozyme Therapeutics (HALO)

There was a first deputy Commissioner named to

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
north40000 Member Profile
Member Level 
Followed By 175
Posts 15,344
Boards Moderated 0
Alias Born 01/19/06
160x600 placeholder
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/1/2019 7:11:11 PM
Halozyme To Participate In 2019 Cantor Global Healthcare Conference PR Newswire (US) - 9/23/2019 8:00:00 AM
Positive Results Announced From Phase 3 Trial Evaluating Fixed-Dose Subcutaneous Combination Of Perjeta® And Herceptin® Usi... PR Newswire (US) - 9/13/2019 1:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/4/2019 11:21:22 AM
Halozyme To Participate In 2019 Wells Fargo Healthcare Conference PR Newswire (US) - 8/26/2019 8:00:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/6/2019 4:19:53 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/6/2019 4:13:31 PM
Halozyme Reports Second Quarter 2019 Results PR Newswire (US) - 8/6/2019 4:01:00 PM
Halozyme To Participate In 39th Annual Canaccord Genuity Growth Conference PR Newswire (US) - 7/25/2019 8:00:00 AM
Halozyme To Host Second Quarter 2019 Financial Results Webcast And Conference Call PR Newswire (US) - 7/23/2019 4:01:00 PM
J&J's Janssen Seeks Europe OK For Subcutaneous Darzalex in Multiple Myeloma Dow Jones News - 7/19/2019 7:45:00 AM
Halozyme Announces Janssen Submits Extension Application To European Medicines Agency For Subcutaneous Formulation Of DARZALE... PR Newswire (US) - 7/19/2019 7:00:00 AM
Halozyme Announces First Clinical Dosing In argenx's Phase 1 Trial Of Efgartigimod (ARGX-113) With ENHANZE® Drug Delivery Te... PR Newswire (US) - 7/17/2019 8:00:00 AM
Halozyme Announces Janssen Submits BLA To FDA For Subcutaneous Formulation Of DARZALEX® Utilizing ENHANZE® Technology PR Newswire (US) - 7/12/2019 11:59:00 AM
Amended Statement of Beneficial Ownership (sc 13d/a) Edgar (US Regulatory) - 7/3/2019 4:02:19 PM
Halozyme Announces CRADA With National Institute of Allergy and Infectious Diseases For Use Of ENHANZE® Drug Delivery Techno... PR Newswire (US) - 6/25/2019 8:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/17/2019 8:20:11 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/12/2019 1:41:16 PM
Amended Statement of Beneficial Ownership (sc 13d/a) Edgar (US Regulatory) - 6/7/2019 5:11:39 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/4/2019 4:45:58 PM
Halozyme To Participate In Upcoming Investor Conferences PR Newswire (US) - 6/4/2019 8:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/3/2019 5:24:28 PM
Halozyme Announces argenx Has Selected Second Target Under ENHANZE® Technology Collaboration And License Agreement PR Newswire (US) - 5/22/2019 1:05:00 AM
Post-effective Amendment to an S-8 Filing (s-8 Pos) Edgar (US Regulatory) - 5/14/2019 5:11:52 PM
Post-effective Amendment to an S-8 Filing (s-8 Pos) Edgar (US Regulatory) - 5/14/2019 5:08:35 PM
north40000 Member Level  Thursday, 03/07/19 08:12:18 AM
Re: Fred Kadiddlehopper post# 5608
Post # of 5692 
There was a first deputy Commissioner named to replace the previous 1st deputy who had retired in January. The new 1st Deputy will be in overall charge of daily operations at FDA once Dr. Gottlieb files his short resignation letter in “a month or so” from yesterday. The new 1st Deputy is a M.D., Ph.D. who looks to be well qualified to run FDA in any absence of Dr. Gottlieb.

We have no idea who the President will appoint to succeed Dr. Gottlieb.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist